Keros Therapeutics Stock (NASDAQ:KROS), Trade Ideas

Keros Therapeutics

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABVC

ACET

AREN

ATIF

ATUS

ATXI

AVNS

FWBI

HKIT

JFBR

KROS

Kintara Therapeutics, Inc. - Common Stock

KTRA

LFMD

MBLY

MINM

MNSO

MOBX

MPLN

NEXI

NKLA

NMRD

NUZE

OMGA

PNST

RDUS

RLMD

SGLY

SMFL

XRTX

YCBD

Shares of  Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.&lt;

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AGTI

ARWR

INSP

PTON

RXRX

XERS

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday.

Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following better-than-expected quarterly results.

Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday

AAGR

APLS

BLUE

BMEA

BPMC

BTBT

CLSK

COMM

CYTO

DISH

DOGZ

EFTR

HIVE

IONM

IPDN

ISUN

JTAI

KTTA

MARA

Morgan Stanley Capital Protected Notes for S&P 500 Index

NXTP

ONTX

RIOT

SHAK

TRKA

VAPO

VERU

WULF

XFOR

ZLAB

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting &amp; Exposition.

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Keros Therapeutics Inc

Macro Economic Events

Global

Economics

U.S. Treasury's Yellen Says overcapacity In China Is Not Just A U.S. Issue, It's An Issue For Europe, Japan And Emerging Markets Like India And Mexico; We Have No Problem With China Producing And Selling Globally; U.S., Europe, Other Countries Want The Ability To Produce Clean Energy Goods

Evercore ISI Group analyst David Togut maintains Western Union (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>) with a In-Line and raises the price target from $14 to $15.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Western Union, Raises Price Target to $15

Evercore ISI Group analyst James West maintains Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) with a Outperform and raises the price target from $130 to $151.

WFRD

Evercore ISI Group Maintains Outperform on Weatherford International, Raises Price Target to $151

S&P Says Boeing Co. Outlook Revised To Negative On Delay Of Credit Metrics Restoration; 'BBB-/A-3' Ratings Affirmed; Boeing Faces Heightened Production Uncertainty, Notably Related To Quality Issues Affecting 737 Max Aircraft, Key Changes To Leadership Pending

Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $98 to $77.

CNMD

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $77

Evercore ISI Group analyst Amit Daryanani maintains Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Outperform and raises the price target from $90 to $95.

Evercore ISI Group Maintains Outperform on Vertiv Hldgs, Raises Price Target to $95

U.S. Treasury's Yellen Says China Has Acknowledged A Problem With Overcapacity; Emphasizing Undesirable Spillovers From Chinese Overcapacity

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) continues to showcase robust performance in its first-quarter earnings <a href="https://www.benzinga.com/quote/NFLX/news">report for 2024</a>. 
The streaming company is now on track to monetize about 40 million borrowers (i.e., people who do not live in the same household but share the same account). 
In order to curb sharers/borrowers of an account outside a household, Netflix has restricted access to sharers beyond a household. The company also devised ways to make it easier for borrowers to transfer Netflix profiles into their own account. 
The initiative ultimately means more paying accounts for Netflix.
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">Netflix Q1 Earnings Highlights: Revenue Beat, EPS Beat, 9.33 Million Paid Subs Added, Ad-Tier Plan Update And More</a>
With revenue surging to $9.37 billion, a 14.8% year-over-year increase, and earnings per share standing at $5.28, surpassing analyst estimates, Netflix demonstrates its resilience and ability to thrive in the ever-evolving media industry. 
The company&#8217;s relentless pursuit of growth is evident in its addition of 9.33 million paid subscribers during the first quarter alone, bringing its total subscriber base to a staggering 269.60 million, marking a significant 16.0% increase from the previous year. Such impressive numbers underscore Netflix&#8217;s unparalleled position as a market leader in the streaming space.
Netflix stock is up 68.72% over the past year, 14.02% YTD.
<h3 class="wp-block-heading">Netflix Strategy Through The Lens Of JPMorgan</h3>
Moreover, insights from JPMorgan&#8217;s Video Streaming Survey shed light on Netflix&#8217;s strategy to further capitalize on its user base. 
The survey reveals 44% of Netflix borrowers in the first quarter indicated their intention to either obtain their own subscription (38%) or become an additional member (6%). This data suggests that Netflix is effectively converting borrowers into paying customers, with projections estimating the potential monetization of approximately 40 million borrowers by the end of 2024. 
Netflix&#8217;s initiatives to curb password sharing and introduce an ad-tier plan are notable developments aimed at enhancing monetization opportunities. 
With 65% of Netflix users now restricted from sharing their accounts outside their households, and a growing awareness of the ad-tier option among subscribers, Netflix is diversifying its revenue streams and catering to varying consumer preferences.
<h2 class="wp-block-heading">Analysts See Over 25% Upside For Netflix Stock</h2>
In light of these developments, analysts remain bullish on Netflix&#8217;s future prospects. 
Following the release of the Q1 earnings report, Evercore ISI Group, B of A Securities, and Oppenheimer issued their latest ratings, collectively assigning an average price target of $691.67 for Netflix stock. This projection implies a substantial 26.03% upside potential, reflecting analysts&#8217; confidence in Netflix&#8217;s ability to capitalize on its expanding subscriber base and innovative monetization strategies.
As Netflix continues to invest in original content, expand its global footprint, and innovate its platform, the company remains poised for sustained growth and profitability. 
With a compelling combination of subscriber growth, revenue diversification, and analyst optimism, Netflix stands at the forefront of the digital entertainment revolution, poised to deliver significant value to both investors and consumers alike.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38429532/bullish-boeing-analyst-says-didnt-expect-things-to-start-falling-apart-in-midair-if">Bullish Boeing Analyst Says &#8216;Didn&#8217;t Expect Things To Start Falling Apart In Midair&#8216;</a>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

NFLX

Netflix Could Monetize 40M Borrowers By End Of 2024, Analysts See Over 25% Upside

Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:
<h3>SPDR S&amp;P 500 ETF Trust</h3>
The SPY (ARCA: SPY) is presently trading around the price of 502.85. The bullish perspective hopes for an initial rise to 503.95. Maintaining strong performance above this mark could usher the SPY towards a subsequent target of 505.32. Should this level prove stable during regular market hours, there may be potential for an ascent to 506.06, with an ambitious high target of 507.52 for today&rsquo;s session.
Conversely, if the SPY fails to maintain support at 502.85, the bearish scenario comes into play. We would anticipate a move down to 501.74, testing market resilience. If bearish momentum persists and the price breaks below this level, a further decline to 500.91 could occur, with an ultimate strong support possibly forming at 500.17. Should today manifest a pronounced downward trend, the price might even reach a lower bear target of 498.93.
<h3>Invesco QQQ Trust Series 1</h3>
The QQQ (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>) , or &quot;the Q&#39;s&quot;, is currently positioned around 422.16. Bullish traders are looking to uphold the price above 423.27, seeking to establish firm support there. If successful, the next target is 424.04, with potential further gains leading to 425.77. Should today&rsquo;s trading conditions be favorable, the bulls may aim for a peak price of 427.32, with the highest target set at 428.50.
On the downside, if 422.16 cannot serve as a stable base during today&rsquo;s trading, bears might push the price down to 420.76. A confirmed weakness could see the QQQ descend to 419.89 and possibly to 419.19 if support levels fail. In a scenario of pronounced bearish pressure, a drop to a lower bearish target of 417.49 might be witnessed.
<h3>Apple Inc.</h3>
Apple&rsquo;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) stock is currently hovering around 168.99. From a bullish viewpoint, maintaining this level is crucial. If support holds, there&#39;s potential for a rise to 169.73, with continued momentum possibly pushing the price to 170.32. If the overall market sentiment remains bullish today, Apple might see a peak target of 171.13.
If Apple&rsquo;s price falls below 168.99 during regular trading hours, it may signal bearish control, prompting a retest at 168.00. Persisting sell-offs could lead to further declines towards 167.59 and 167.09. In a significant downturn, the price might gravitate towards the day&rsquo;s low bear target of 166.27.
<h3>Microsoft Corp. </h3>
Microsoft&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) is trading near 400.30. Bulls aim to keep the price above 401.39 and strengthen it up to 402.74, solidifying it as a support level. Sustained buying could propel the stock towards 404.92, aiming for the highest bullish target of 406.01 for the day.
If support at 400.30 gives way, a bearish outlook suggests a possible dip to 399.21. If this level cannot hold, further declines to 398.38 and 397.65 could be expected. The lowest bear target for Microsoft today is set at 395.68.
<h3>NVIDIA Corporation</h3>
NVIDIA&rsquo;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) stock is being watched closely at the 799.10 mark. Bulls are looking to propel it initially to 804.61 and establish clear support. With continued buying interest, a push towards 810.13 and possibly up to 816.95 could be seen, setting a high target of 823.52 for the day.
However, if NVIDIA cannot maintain the 799.10 level as a strong support today, bears may look to decrease the price to 794.94. If selling intensifies, a further drop to 791.44 and then to 781.59 could occur. In a substantial bearish trend, the day&rsquo;s low target could be 775.50.
<h3>Alphabet Inc Class A</h3>
Alphabet&rsquo;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) current level is 154.44. Bulls seek to stabilize the price at 154.95 and advance it to 155.59. With ongoing bullish momentum, the price might aim for today&rsquo;s high target of 156.61.
Should the price fall below 154.44, bears might drive it down to 153.54. If this level fails to hold, the price might be pushed further to 152.94, and in a significant sell-off, down to a low bear target of 152.27.
<h3>Meta Platforms Inc</h3>
Meta&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is trading around 420.24. Bulls are keen on supporting the price here and pushing it higher to 426.00. Strong buying could lead to further advances towards 429.01, with a potential high target of 436.87.
Conversely, if 420.24 fails as a support level, bears might force the price down to 417.87. Continuing bearish trends could lead to further declines to 412.80, and if not held, down to the day&rsquo;s low bear target of 409.16.
<h3>Tesla Inc.</h3>
Tesla&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) is currently priced around 160.32. Bulls hope to drive the price up to 162.32 and further to 164.87. A bullish market trend today could see Tesla potentially reaching 166.89, with an optimistic high target of 169.70.
If Tesla&rsquo;s price does not maintain the 160.32 level, it might be tested lower at 158.92, potentially falling to 157.52. Should selling pressure persist, the price could decline to a day&rsquo;s low target of 152.97.
Final Word: Today&#39;s trading session is packed with key economic data releases that could significantly influence market dynamics. Beginning at 8:30 AM ET, we have the announcement of the GDP and Core PCE Price Index for the first quarter, coupled with the latest unemployment figures. These data points are crucial as they offer insights into the economic health and inflationary pressures, setting the tone for market volatility.
Following the morning data, the market will shift its focus to the Pending Home Sales report for March, which is scheduled for release at 10 AM ET. This indicator provides further context on the real estate market, which has implications for broader economic conditions.
In the afternoon, attention turns to the government sector with a 7 Year Note Auction from the Treasury at 1 PM ET. The outcome of this auction could impact interest rates and investor sentiment.
Wrapping up the day, the post-market hours will see key earnings announcements from major tech companies including Microsoft, Alphabet, and Intel. These earnings results are highly anticipated, as they have the potential to influence market trends and investor confidence.
Given this lineup of events, traders should be prepared for a day marked by potentially high volatility and dynamic shifts in market sentiment. It&rsquo;s advisable to stay informed, monitor the markets closely, and trade cautiously. Good luck today!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

General

AAPL

GOOGL

MSFT

NVDA

TSLA

Market Clubhouse Morning Memo - April 25th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, And TSLA)

Evercore ISI Group analyst Thomas Gallagher maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Underperform and raises the price target from $115 to $116.

Evercore ISI Group Maintains Underperform on Prudential Financial, Raises Price Target to $116

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $72 to $82.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $82

Federal Reserve

U.S. Treasury's Yellen Says Europeans Have Taken Very Constructive Step On Frozen Russian Assets By Segregating Profits And Agreeing To Transfer To Ukraine; There Are A Range Of Options, Want To Give Several Options To G7 Leaders

Evercore ISI Group analyst Jonathan Chappell maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Outperform and lowers the price target from $241 to $225.

ODFL

Evercore ISI Group Maintains Outperform on Old Dominion Freight Line, Lowers Price Target to $225

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and raises the price target from $100 to $110.

BMRN

Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $110

U.S. Treasury's Yellen Says We Have Raised Estimate Of Spending Associated With Clean Energy Tax Credits, But This Will Make American Economy More Secure

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.

Reiteration

AMED

Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target

Management

Whirlpool In Q1 Earnings Report Said "In March 2024, The Co Committed To Workforce Reduction Plans. $23M Was Recorded During Q1 Of Which $14M Was Employee Termination Costs And $9M Was Other Associated Exit Costs. For FY24, We Expect To Incur ~$50M Of Restructuring Charges"

Evercore ISI Group analyst Stephen Kim maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a In-Line and raises the price target from $154 to $172.

Evercore ISI Group Maintains In-Line on Owens-Corning, Raises Price Target to $172

Caterpillar Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) reported a&nbsp;first-quarter fiscal 2024&nbsp;revenue of $15.8 billion, a slight decrease of 0.4% year-over-year,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38425106/caterpillar-reports-first-quarter-2024-results" rel="noreferrer noopener">missing the consensus of $16.216 billion.&nbsp;</a>
CAT&#8217;s adjusted earnings of $5.60 per share, compared to $4.91 a year ago, <a href="https://www.benzinga.com/calendars/earnings">topped the consensus of $5.14.</a>
Sales dropped due to reduced equipment sales, somewhat mitigated by favorable pricing and increased Financial Products&#8217; revenues; adverse currency impacts, mainly from the Australian dollar, also affected overall sales.
Adjusted operating profit margin was 22.2% for the quarter, compared with 21.1% for the first quarter of 2023.
Enterprise operating cash flow was $2.05 billion for the quarter, and the company ended the first quarter with $4.96 billion of enterprise cash.
Caterpillar deployed $4.5 billion of cash for repurchases of Caterpillar common stock and $0.6 billion&nbsp;of cash&nbsp;for dividends in the quarter.
Machinery, Energy &amp; Transportation segment revenue declined 0.9% Y/Y, with Construction Industries down 5%, Resource Industries down 7%, Energy &amp; Transportation&nbsp;up&nbsp;7%, and Other Segments down 2%.
Financial Products revenues increased by 10% Y/Y to $839 million.
2024 Outlook:&nbsp;Caterpillar anticipates sales and revenues&nbsp;to be&nbsp;broadly similar to 2023.
The company sees no significant change in machine dealer inventory by the end of 2024, as compared to a build in 2023.
CAT expects 2024 adjusted operating profit margin to be in the top half of the target range relative to the expected corresponding level of sales and revenues.
For the second quarter, Caterpillar expects sales to be lower than the prior year, price realization to remain favorable, and adjusted operating profit margin to <a href="https://www.benzinga.com/calendars/guidance">be similar to the prior year.</a>
Price Action: CAT shares are trading lower by 7.51% at $336.22 at the last check Thursday.
Photo via Shutterstock

Earnings

Equities

Guidance

Why Is Equipment Giant Caterpillar Stock Plunging Today?

U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday.
Shares of Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) rose sharply during Thursday's session following better-than-expected <a href="https://www.benzinga.com/general/biotech/24/04/38432249/drugmaker-sanofis-strong-dupixent-and-beyfortus-vaccine-sales-propel-q1-earnings">first-quarter earnings</a>.
Sanofi reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of 97 cents (1.78 euros), beating the consensus estimate of 94 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Sanofi shares climbed 5.5% to $49.15 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>P.A.M. Transportation Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTSI#NASDAQ">PTSI</a>) jumped 19.8% to $17.42 after the company announced a self-tender offer to purchase up to 550,000 shares at a price not less than $15.50-$18.00 per share.</li>
<li>Ultralife Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) shares jumped 16.6% to $10.19 after the company reported better-than-expected quarterly financial results.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) rose 16% to $140.21 after reporting better-than-expected first-quarter financial results.</li>
<li>Sleep Number Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) climbed 11.5% to $15.13 following first-quarter results.</li>
<li>Strategic Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) shares gained 10% to $110.78 following upbeat results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 9.6% to $459.39 after the company reported better-than-expected first-quarter EPS and sales. Additionally, the company provided upbeat guidance for FY24.</li>
<li>TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) surged 8.9% to $74.83 after the company reported better-than-expected first-quarter financial results. The company also provided upbeat guidance for second quarter.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) rose 7.9% to $3.27 after the company reported better-than-expected first-quarter financial results.</li>
<li>Kirby Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) shares gained 7.6% to $108.69 following better-than-expected first-quarter results.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) climbed 7.6% to $17.78 following strong earnings.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) rose 6.8% to $17.61 after the company reported better-than-expected first-quarter financial results.</li>
<li>Sonic Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) shares gained 6.7% to $54.57 following upbeat earnings.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) surged 6.3% to $58.21 following first-quarter earnings.</li>
<li>AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) climbed 5.8% to $75.35 following a first-quarter revenue beat.</li>
<li>Teradyne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TER#NYSE">TER</a>) shares rose 5% to $105.71 after the company posted upbeat first-quarter results and issued strong second-quarter forecast.</li>
<li>Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) shares gained 4.4% to $242.28 after the company reported better-than-expected first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38428592/how-to-earn-500-a-month-from-t-mobile-us-stock-ahead-of-q1-earnings-report">How To Earn $500 A Month From T-Mobile US Stock Ahead Of Q1 Earnings Report</a>

CARR

PTSI

SNBR

STRA

ULBI

Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday

An update from Keros Therapeutics (KROS) is now available. Keros Therapeutics, Inc. has announced that its President and CEO, Jasbir Seehra, will b...

Keros Therapeutics CEO to Speak at Global Biopharma Conference

The latest announcement is out from Keros Therapeutics (KROS). Simon Cooper, the Chief Medical Officer of Keros Therapeutics, has voluntarily resig...

Keros Therapeutics CMO Simon Cooper Resigns

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Keros Therapeutics (KROS – Research Report) today. The company's shares cl...

Keros Therapeutics (KROS) Gets a Buy from Truist Financial

Keros Therapeutics (KROS) has issued an announcement. Keros Therapeutics, Inc. has refreshed its corporate presentation, which is now accessible on...

Keros Therapeutics Updates Corporate Presentation Online

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today. The company's shares cl...

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $85.00. Tho...

Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $105....

Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Iridex (IRIX – Research Repor...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)

The 65 rating InvestorsObserver gives to Keros Therapeutics Inc (KROS)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, KROSâ€&#x2122;s 65 overall rating means the stock scores better than 65 percent of all stocks. KROS has an Overall S

Should Biotechnology Stock Keros Therapeutics Inc (KROS) Be in Your Portfolio Wednesday?

In a report released on March 27, Thomas Smith from Leerink Partners reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), with a...

Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012

ARGX

IRIX

Health Care

Press Releases

Keros Therapeutics to Present at Upcoming Healthcare Conferences

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Financing

Keros Therapeutics Announces Proposed Public Offering of Common Stock

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes